Pregnancy-associated breast cancer is as chemosensitive as non-pregnancy-associated breast cancer in the neoadjuvant setting

Annals of Oncology

Volumn 22, Issue 7, 2011, Pages 1582-1587

  Rouzier, R ^a,b,c   Werkoff, G ^b,c   Uzan, C ^a,d   Mir, O ^a,b,e   Gligorov, J ^a,b   Selleret, L ^a,b   Goffinet, F ^a,b,e   Goldwasser, F ^b,e   Treluyer, J M ^a,b,e   Uzan, S ^a,b,c   Delaloge, S ^a,d  

^a CALG Cancers AssociésàLa Grossesse Network   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Breast; Cancer; Chemotherapy; Neoadjuvant; Nomogram; Pregnancy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADULT; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CALIBRATION; CHEMOSENSITIVITY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MASTECTOMY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NOMOGRAM; PARTIAL MASTECTOMY; PREDICTION; PREGNANCY; PRIORITY JOURNAL; PROBABILITY; PUERPERIUM; TREATMENT RESPONSE;

EID: 79959758719     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq642     Document Type: Article

References (26)

1. Pentheroudakis G, Pavlidis N. Cancer and pregnancy: poena magna, not anymore. Eur J Cancer 2006; 42: 126-140.
2. Reed W, Hannisdal E, Skovlund E et al. Pregnancy and breast cancer: a population-based study. Virchows Arch 2003; 443: 44-50.
3. Gonzalez-Angulo AM, Broglio K, Kau SW et al. Women age < or = 35 years with primary breast carcinoma: disease features at presentation. Cancer 2005; 103: 2466-2472.
4. Mathelin C, Annane K, Treisser A et al. Pregnancy and post-partum breast cancer: a prospective study. Anticancer Res 2008; 28: 2447-2452.
5. Eedarapalli P, Jain S. Breast cancer in pregnancy. J Obstet Gynaecol 2006; 26: 1-4.
6. Woo JC, Yu T, Hurd TC. Breast cancer in pregnancy: a literature review. Arch Surg 2003; 138: 91-98.
7. Berry DL, Theriault RL, Holmes FA et al. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol 1999; 17: 855-861.
8. Mir O, Berveiller P, Ropert S et al. Emerging therapeutic options for breast cancer chemotherapy during pregnancy. Ann Oncol 2008; 19: 607-613.
9. Ring AE, Smith IE, Jones A et al. Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. J Clin Oncol 2005; 23: 4192-4197.
10. Rouzier R, Extra JM, Klijanienko J et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 2002; 20: 1304-1310.
11. Rouzier R, Pusztai L, Delaloge S et al. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 2005; 23: 8331-8339.
12. Rouzier R, Coutant C, Lesieur B et al. Direct comparison of logistic regression and recursive partitioning to predict chemotherapy response of breast cancer based on clinical pathological variables. Breast Cancer Res Treat 2009; 117: 325-331.
13. Singletary SE, Allred C, Ashley P et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002; 20: 3628-3636.
14. Mathieu MC, Rouzier R, Llombart-Cussac A et al. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 2004; 40: 342-351.
15. Rouzier R, Pusztai L, Garbay JR et al. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. Cancer 2006; 107: 1459-1466.
16. Coutant C, Olivier C, Lambaudie E et al. Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. J Clin Oncol 2009; 27: 2800-2808.
17. Loibl S, von Minckwitz G, Gwyn K et al. Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer 2006; 106: 237-246.
18. Polyak K. Pregnancy and breast cancer: the other side of the coin. Cancer Cell 2006; 9: 151-153.
19. Schedin P. Pregnancy-associated breast cancer and metastasis. Nat Rev Cancer 2006; 6: 281-291.
20. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004; 5: 283-291.
21. Gonzalez-Angulo AM, McGuire SE, Buchholz TA et al. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol 2005; 23: 7098-7104.
22. Rajan R, Poniecka A, Smith TL et al. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer 2004; 100: 1365-1373.
23. Hennessy BT, Hortobagyi GN, Rouzier R et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 2005; 23: 9304-9311.
24. Giacalone PL, Laffargue F, Benos P. Chemotherapy for breast carcinoma during pregnancy: A French national survey. Cancer 1999; 86: 2266-2272.
25. Hahn KM, Johnson PH, Gordon N et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 2006; 107: 1219-1226.
26. Mir O, Berveiller P, Goffinet F et al. Taxanes for breast cancer during pregnancy: a systematic review. Ann Oncol 2010; 21: 425-426.